Randomized Controlled Trial for EGFR-TKIs Plus S-1 or EGFR-TKIs as the First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900020520

Enrollment

Unknown

Registered

2019-01-06

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

A:EGFR-TKIs plus S-1

B:EGFR-TKIs

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The patients with advanced non-small cell lung cancer harboring EGFR mutations; (2) The body functional state score(ecog) 0-2 points; (3) The expected survival time more than three months; (4) The peripheral blood white blood cells was greater than or equal to 3.5 x 10^9; (5) All cases were evaluated?the efficacy and safety.

Exclusion criteria

Exclusion criteria: 1. Patients who have developed major organ failure; 2. Patients who have had or have had any malignant tumors in the past 5 years except those who have been treated for basal or squamous cell carcinoma of the skin, cervical or bladder, and breast carcinoma in situ; 3. The patients were treated with radiotherapy, targeted?therapies or biotherapy; 4. Pregnant or breastfeeding women.

Design outcomes

Primary

Measure	Time frame
progression-free survival;	—

Secondary

Measure	Time frame
overall survival;ORR;DCR;Qol;AE;	—

Countries

China

Contacts

Public ContactYanhua Jia

Liuzhou General Hospital

13633095654@163.com+86 13633095654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026